Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Invitae | RCV001314424 | SCV001504958 | pathogenic | not provided | 2022-11-15 | criteria provided, single submitter | clinical testing | This variant disrupts the p.Ser391 amino acid residue in USH2A. Other variant(s) that disrupt this residue have been observed in individuals with USH2A-related conditions (PMID: 24944099), which suggests that this may be a clinically significant amino acid residue. Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt USH2A protein function. ClinVar contains an entry for this variant (Variation ID: 1015542). This missense change has been observed in individual(s) with clinical features of Usher syndrome (PMID: 15325563; Invitae). In at least one individual the data is consistent with being in trans (on the opposite chromosome) from a pathogenic variant. This variant is present in population databases (no rsID available, gnomAD 0.0009%). This sequence change replaces serine, which is neutral and polar, with isoleucine, which is neutral and non-polar, at codon 391 of the USH2A protein (p.Ser391Ile). For these reasons, this variant has been classified as Pathogenic. |
Natera, |
RCV001830281 | SCV002094000 | uncertain significance | Usher syndrome type 2A | 2021-08-18 | no assertion criteria provided | clinical testing |